Skip to main content
Evolent Level 1 Medical Oncology

Pathways and Low-Value Regimens

Testicular Cancer

Regimen Options
Last Updated: 06/03/2024 See Details
Evolent Pathways Febrile Neutropenic Risk Emetogenic Risk References
PURE SEMINOMA

Initial (Stage I-III)

carboplatin *Stage 1A, 1B*

Low High
 

etoposide and cisplatin (EP)

Intermediate High
 

bleomycin, etoposide and cisplatin (BEP)

Intermediate High

Subsequent Therapy

VeIP (vinblastine, ifosfamide and cisplatin)

High High
 

TIP (paclitaxel, ifosfamide and cisplatin)

High High
 

gemcitabine and oxaliplatin

Low Moderate
 

gemcitabine and paclitaxel

Low Low
 

etoposide (oral)

Low High
 

Best Supportive Care or Clinical Trial

NON-SEMINOMA

Initial (Stage I-III)

etoposide and cisplatin (EP)

Intermediate High
 

bleomycin, etoposide and cisplatin (BEP)

Intermediate High
 

etoposide, ifosfamide and cisplatin (VIP)

High High

Brain Metastases (+/- RT, +/- surgery)

bleomycin, etoposide and cisplatin (BEP)

Intermediate High
 

etoposide, ifosfamide and cisplatin (VIP)

High High

Subsequent Therapy

etoposide and cisplatin (EP)

Intermediate High
 

VeIP (vinblastine, ifosfamide and cisplatin)

High High
 

TIP (paclitaxel, ifosfamide and cisplatin)

 

High High
 

Best Supportive Care or Clinical Trial

PURE SEMINOMA

Initial (Stage I-III)

Evolent Pathways

etoposide and cisplatin (EP)

Febrile Neutropenic Risk
intermediate
Emetogenic Risk
high
Evolent Pathways

bleomycin, etoposide and cisplatin (BEP)

Febrile Neutropenic Risk
intermediate
Emetogenic Risk
high

Subsequent Therapy

Evolent Pathways

VeIP (vinblastine, ifosfamide and cisplatin)

Febrile Neutropenic Risk
high
Emetogenic Risk
high
Evolent Pathways

TIP (paclitaxel, ifosfamide and cisplatin)

Febrile Neutropenic Risk
high
Emetogenic Risk
high
Evolent Pathways

gemcitabine and oxaliplatin

Febrile Neutropenic Risk
low
Emetogenic Risk
moderate
Evolent Pathways

gemcitabine and paclitaxel

Febrile Neutropenic Risk
low
Emetogenic Risk
low
Evolent Pathways

etoposide (oral)

Febrile Neutropenic Risk
low
Emetogenic Risk
high
Evolent Pathways

Best Supportive Care or Clinical Trial

NON-SEMINOMA

Initial (Stage I-III)

Evolent Pathways

etoposide and cisplatin (EP)

Febrile Neutropenic Risk
intermediate
Emetogenic Risk
high
Evolent Pathways

bleomycin, etoposide and cisplatin (BEP)

Febrile Neutropenic Risk
intermediate
Emetogenic Risk
high
Evolent Pathways

etoposide, ifosfamide and cisplatin (VIP)

Febrile Neutropenic Risk
high
Emetogenic Risk
high

Brain Metastases (+/- RT, +/- surgery)

Evolent Pathways

bleomycin, etoposide and cisplatin (BEP)

Febrile Neutropenic Risk
intermediate
Emetogenic Risk
high
Evolent Pathways

etoposide, ifosfamide and cisplatin (VIP)

Febrile Neutropenic Risk
high
Emetogenic Risk
high

Subsequent Therapy

Evolent Pathways

etoposide and cisplatin (EP)

Febrile Neutropenic Risk
intermediate
Emetogenic Risk
high
Evolent Pathways

VeIP (vinblastine, ifosfamide and cisplatin)

Febrile Neutropenic Risk
high
Emetogenic Risk
high
Evolent Pathways

TIP (paclitaxel, ifosfamide and cisplatin)

 

Febrile Neutropenic Risk
high
Emetogenic Risk
high
Evolent Pathways

Best Supportive Care or Clinical Trial